Tamtam Try Tamtam free
Claritev logo

Claritev account plan

Healthcare pricing transparency solutions

At a glance

Claritev (formerly MultiPlan) is a US healthcare technology and data company that prices claims for over 750 payers; FY2025 revenues $965.4 million.

Claritev, formerly MultiPlan, is a US healthcare technology, data and insights company founded in 1980 that helps payers cut medical costs, mostly by repricing out-of-network claims before they are paid. It works directly with over 750 payers (ASO platforms, TPAs, carriers) and its clients served over 100,000 self-insured employers and plan sponsors in 2025; substantially all revenue is in the United States. FY2025 revenues were $965.4 million (+3.7%), Adjusted EBITDA $602.6 million and net loss $284.3 million, with approximately 3,000 full-time employees at December 31, 2025. It is listed on the NYSE (CTEV); H&F and the Sponsor own a significant equity interest.

Business units

Strategic priorities

Vision 2030 growth strategy
Created in 2024, Vision 2030 sells horizontal solutions into vertical markets (payers, TPAs, employers, providers, government, international). 2025 was branded "THE TURN" and 2026 "THE WAY UP"; $45.0 million of transformation costs were incurred in 2025.
Diversification beyond payers
In Q3 2026, 26% of year-to-date bookings came from TPAs and 25% from newer markets (provider, public sector, international); pipeline is up about 60% year over year, with less than half from payers. TPAs were expected to bring roughly 30% of 2026 new bookings.
Bookings growth
More than $100 million of ACV was booked year to date by Q3 2026 against $67 million for all of 2025; full-year ACV bookings are expected at $115-125 million (70% to 90% growth).
AI across workflows
Dozens of AI agents are in production, the Chief Digital Officer's team has four dozen AI scientists, and 53% of code was delivered with AI in Q1 2026, with 60% to 80% targeted by year end. AI is aimed first at NSA disputes, then manual intake, claims processing and sales lead targeting.
Free cash flow and deleveraging
Returning to positive free cash flow is management's "number one financial priority"; Q4 2026 free cash flow is expected at $74-84 million, and net leverage was 7.7 times in Q3 2026. The long-term aim is "a Rule of 70 company".

Latest results

In Q3 2026 (quarter ended September 30, 2026) revenues were $268.3 million, up 9.1% from $246.0 million, the sixth consecutive quarter of year-over-year growth; nine-month revenues were $770.5 million (+7.2%). Claims Intelligence grew 17.1% while Network fell 5.6% and Payment and Revenue Integrity fell 9.8%. Net loss narrowed to $61.8 million (from $69.8 million) and Adjusted EBITDA was $162.0 million, with margin down to 60.4% from 63.1%. Free Cash Flow was $(25.8) million and unrestricted cash $10.1 million at quarter end. FY2026 guidance was raised to revenues of $1.038-1.043 billion, Adjusted EBITDA of $625-630 million and Free Cash Flow of $10-20 million, with preliminary 2027 revenue expectations of $1.1 billion.

Investments and deals

January 2025 refinancing
New First Lien Term Loans ($325.0 million first-out and $1,143.9 million second-out, maturing December 31, 2030) and a $350.0 million revolver maturing December 31, 2029; long-term debt was $4,560.4 million at December 31, 2025.
Technology transformation capex
FY2026 capex guidance is $165-170 million; nine-month 2026 investing outflow rose to $128.8 million on investment in technologies for the transformation. Most applications have moved to the cloud on a new data architecture, and a new ERP system was implemented.
OPCG asset acquisition
On November 10, 2025 Claritev acquired OPCG, LLC assets for $4.8 million in cash, adding healthcare program management and consulting expertise.
MENA expansion
In 2025 Claritev made its first international expansion, into the MENA region, through a partnership with Claims Care, a division of Burjeel Holdings.
Go-to-market investment
$20 to $25 million of planned 2026 investment in sales, marketing, go-to-market and delivery, alongside a five-year share repurchase program of up to $75.0 million (2026-2030).

Challenges and risks

Client concentration
Two clients were 29.2% and 10.4% of FY2025 revenues, and one client accounted for 38.0% of Q3 2026 revenue.
Heavy leverage and thin liquidity
Long-term debt was $4,560.4 million at end-2025 with $392.0 million of interest expense; at Q3 2026 cash and cash equivalents were $10.1 million and $95.0 million was drawn on the $350.0 million revolver.
Antitrust litigation
Antitrust class actions alleging suppression of out-of-network reimbursements are centralized in the Northern District of Illinois with discovery ongoing; the DOJ issued a civil investigative demand on May 19, 2026. Antitrust legal expenses were $21.5 million for the first nine months of 2026.
IT control material weaknesses
Material weaknesses in IT general controls (program change management and user access) found at December 31, 2025 remained unremediated at September 30, 2026; remediation is expected in fiscal 2026.
Payment and Revenue Integrity behind plan
PRI revenue fell 9.8% in Q3 2026 as clinical negotiations moved into Claims Intelligence; only about 20% of more than $40 million of PRI ACV booked over four quarters had converted to revenue.

What leadership says

“Claritev is a growth company, period.”

Travis Dalton, Chairman, CEO and President · Claritev Q3 2026 earnings call, November 9, 2026

“We are not a widget or a point solution looking for an exit or a home.”

Travis Dalton, Chairman, CEO and President · Claritev Q3 2026 earnings call, November 9, 2026

“running approximately a year ahead of our March 2026 Investor Day plan, with preliminary 2027 revenue expectations of $1.1 billion”

Doug Garis, CFO · Claritev Q3 2026 results press release, November 9, 2026

“No company has demonstrated a greater ability to manage NSA claims at scale than Claritev.”

Travis Dalton, President and CEO · Claritev Q2 2026 earnings call, August 7, 2026

Where a supplier can help

AI and automation tooling
Tied to the AI-across-workflows priority: with dozens of agents in production and a target of 60% to 80% of code delivered with AI, suppliers of AI development, model operations and claims-intake automation have a stated buyer.
IT controls and security remediation
Tied to the unremediated IT general control material weaknesses: providers of access management, change management and audit-readiness tooling or services fit a remediation due in fiscal 2026.
Go-to-market for new verticals
Tied to the diversification priority and the $20 to $25 million of 2026 go-to-market investment: sales enablement, partner channel and market-data suppliers can support selling into TPAs, providers, public sector and international markets.
Cloud cost and hosting efficiency
Tied to the free cash flow priority and rising software hosting costs in G&A: cloud cost optimisation and infrastructure efficiency offerings align with management's push to improve free cash flow conversion.
Legal and dispute operations
Tied to the antitrust litigation challenge and the NSA dispute volumes: e-discovery, legal operations and dispute-processing services address costs the documents name.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Claritev?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Claritev

What does Claritev do?

Claritev is a US healthcare technology, data and insights company that helps payers cut medical costs, mainly by pricing out-of-network claims before payment. It also runs one of the largest US provider networks, payment integrity services and data analytics products.

What is Claritev's revenue?

FY2025 revenues were $965.4 million, up 3.7%. For FY2026 the company guides to revenues of $1.038-1.043 billion and expects at least $1.1 billion in 2027.

How many employees does Claritev have?

Claritev had approximately 3,000 full-time employees at December 31, 2025.

What is Claritev's strategy?

Vision 2030 sells horizontal solutions into vertical markets such as payers, TPAs, employers, providers, government and international, backed by AI investment. 2026 is branded "THE WAY UP", with priorities of growth in the core, diversification, free cash flow and delevering.

Who leads Claritev?

Travis S. Dalton is President, CEO and Executive Chair, and Douglas M. Garis is EVP and CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)